Evaluation of Trontinemab Distribution, Binding, and Retention in the Brain of Healthy Subjects and Alzheimer’s Disease Patients

The primary objective of this study is to evaluate the **distribution**, **binding**, and **retention** of the monoclonal antibody Trontinemab in the brain of healthy participants and patients with **Alzheimer's Disease (AD)**. Understanding these pharmacokinetic properties is clinically relevant as it may provide insights into the potential efficacy and safety of Trontinemab as a therapeutic agent for Alzheimer's Disease. The study aims to determine how effectively Trontinemab can target and remain in the brain, which is crucial for its potential role in modifying disease progression or symptoms in Alzheimer's Disease.

The clinical trial involves participants diagnosed with **Alzheimer's Disease (AD)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. Participants' general health status, lifestyle considerations such as diet, physical activity, or habits, and specific inclusion or exclusion criteria have not been disclosed. The trial aims to gather data from a diverse group of individuals affected by this neurodegenerative condition.

The clinical trial is designed to evaluate the **distribution**, binding, and retention of the monoclonal antibody Trontinemab in the brain of healthy participants and patients with **Alzheimer's Disease**. This study is a Phase 3 trial, employing a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The trial is expected to commence recruitment on November 14, 2024, and is anticipated to conclude by April 14, 2025. Participants will be involved in the study for the duration of the trial, with specific timelines for each phase of participation.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study groups. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, the effects of the intervention, and to collect necessary data. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather concluding data on the study's primary and secondary endpoints.

Participant involvement is expected to last until the end of the trial, unless specific conditions necessitate early termination. Such conditions may include adverse reactions, withdrawal of consent, or any other protocol-defined criteria that compromise the safety or integrity of the study. The trial's methodology and design are structured to maintain scientific rigor and ensure the ethical treatment of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on November 14, 2024, with an estimated completion date of April 14, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger population. The trial's design will likely include regular assessments at specified intervals to monitor progress and gather data, although specific timepoints and tools are not provided in the current information.